Kythera Biopharmaceuticals Company Profile (NASDAQ:KYTH)

About Kythera Biopharmaceuticals

Kythera Biopharmaceuticals logoKYTHERA Biopharmaceuticals, Inc. (KYTHERA) is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company's initial focus is on the facial aesthetics market. The Company's product candidate is ATX101, an injectable drug in late-stage clinical development for the treatment of submental fullness associated with submental fat, which commonly presents as an undesirable double chin. ATX101 is a formulation of a purified synthetic version of deoxycholic acid. The Company has completed Phase III clinical trials for ATX101 and has made regulatory filings outside the United States, in Canada, Switzerland and Australia.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: KYTH
  • CUSIP: 50157010
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $74.78
  • 200 Day Moving Average: $62.97
  • 52-Week Range: $29.86 - $76.31
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -22.72
  • P/E Growth: 0.00
  • Market Cap: $N/A
Additional Links:
Companies Related to Kythera Biopharmaceuticals:

Analyst Ratings

Consensus Ratings for Kythera Biopharmaceuticals (NASDAQ:KYTH) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Kythera Biopharmaceuticals (NASDAQ:KYTH)
DateFirmActionRatingPrice TargetDetails
6/29/2015Leerink SwannDowngradeOutperform -> Market Perform$61.00 -> $75.00View Rating Details
6/8/2015GuggenheimInitiated CoverageBuy$64.00View Rating Details
4/10/2015Bank of America Corp.Initiated CoverageBuy$66.00 -> $47.00View Rating Details
11/11/2014FBR & CoLower Price TargetOutperform$62.00 -> $59.00View Rating Details
(Data available from 10/25/2014 forward)


Earnings History for Kythera Biopharmaceuticals (NASDAQ:KYTH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/5/2015Q2($1.15)($1.44)ViewN/AView Earnings Details
5/7/2015Q115($1.12)$1.24ViewN/AView Earnings Details
3/2/2015Q414($1.07)($1.07)ViewN/AView Earnings Details
8/7/2014Q2($0.83)($0.86)ViewListenView Earnings Details
5/8/2014Q1($0.67)($3.18)ViewListenView Earnings Details
3/17/2014Q413($0.69)($0.66)ViewN/AView Earnings Details
11/14/2013Q313($0.72)($0.62)ViewN/AView Earnings Details
8/6/2013Q2 2013($0.70)($0.67)ViewN/AView Earnings Details
5/13/2013Q1 2013($0.97)($0.77)ViewN/AView Earnings Details
3/21/2013Q4 2012($0.76)($1.04)ViewN/AView Earnings Details
11/13/2012Q312($11.41)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Kythera Biopharmaceuticals (NASDAQ:KYTH)
Current Year EPS Consensus Estimate: $-4.45 EPS
Next Year EPS Consensus Estimate: $-3.30 EPS


Dividend History for Kythera Biopharmaceuticals (NASDAQ:KYTH)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Kythera Biopharmaceuticals (NASDAQ:KYTH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/24/2015Frederick Beddingfield IIIinsiderSell110,638$74.91$8,287,892.58View SEC Filing  
9/24/2015John W. SmitherCFOSell53,835$74.90$4,032,241.50View SEC Filing  
9/23/2015Elisabeth SandovalinsiderSell83,122$74.90$6,225,837.80View SEC Filing  
9/23/2015Keith KleinGeneral CounselSell52,153$74.90$3,906,259.70View SEC Filing  
9/22/2015John W. SmitherCFOSell6,645$74.91$497,776.95View SEC Filing  
9/22/2015Keith KleinGeneral CounselSell10,589$74.90$793,116.10View SEC Filing  
9/18/2015John W. SmitherCFOSell1,054$74.95$78,997.30View SEC Filing  
9/1/2015Camille D SamuelsDirectorSell250$74.72$18,680.00View SEC Filing  
6/25/2015Frederick Beddingfield IIIInsiderSell30,583$75.66$2,313,909.78View SEC Filing  
6/25/2015John W SmitherCFOSell4,600$75.50$347,300.00View SEC Filing  
5/1/2015Keith R LeonardCEOSell13,000$44.93$584,090.00View SEC Filing  
4/30/2015Elisabeth SandovalInsiderSell1,654$45.55$75,339.70View SEC Filing  
4/30/2015John W SmitherCFOSell2,041$45.49$92,845.09View SEC Filing  
4/30/2015Keith R LeonardCEOSell5,557$45.29$251,676.53View SEC Filing  
4/15/2015Keith R LeonardCEOSell2,709$50.52$136,858.68View SEC Filing  
4/1/2015Keith R LeonardCEOSell13,548$48.14$652,200.72View SEC Filing  
3/16/2015Keith R LeonardCEOSell5,312$50.16$266,449.92View SEC Filing  
3/9/2015Nathaniel E DavidDirectorSell6,185$55.00$340,175.00View SEC Filing  
3/5/2015John W SmitherCFOSell4,200$48.09$201,978.00View SEC Filing  
3/5/2015Nathaniel E DavidDirectorSell12,375$48.49$600,063.75View SEC Filing  
3/2/2015Keith R LeonardCEOSell10,625$40.94$434,987.50View SEC Filing  
3/2/2015Nathaniel E DavidDirectorSell1,875$40.78$76,462.50View SEC Filing  
2/18/2015John W SmitherCFOSell2,000$41.00$82,000.00View SEC Filing  
2/17/2015Keith R LeonardCEOSell4,165$40.46$168,515.90View SEC Filing  
2/2/2015Keith R LeonardCEOSell6,249$36.70$229,338.30View SEC Filing  
2/2/2015Nathaniel E DavidDirectorSell1,715$36.76$63,043.40View SEC Filing  
1/29/2015John W SmitherCFOSell1,000$38.00$38,000.00View SEC Filing  
1/23/2015John W SmitherCFOSell3,000$35.65$106,950.00View SEC Filing  
1/16/2015Camille D SamuelsDirectorSell250$36.70$9,175.00View SEC Filing  
1/2/2015Keith R LeonardCEOSell6,120$35.37$216,464.40View SEC Filing  
1/2/2015Nathaniel E DavidDirectorSell1,680$35.30$59,304.00View SEC Filing  
12/1/2014Keith R LeonardCEOSell5,994$37.60$225,374.40View SEC Filing  
12/1/2014Nathaniel E DavidDirectorSell1,645$37.67$61,967.15View SEC Filing  
11/3/2014Keith R LeonardCEOSell5,865$34.95$204,981.75View SEC Filing  
11/3/2014Nathaniel E DavidDirectorSell1,610$34.90$56,189.00View SEC Filing  
10/23/2014Keith R LeonardCEOSell1,913$35.13$67,203.69View SEC Filing  
10/1/2014Keith R LeonardCEOSell3,826$32.55$124,536.30View SEC Filing  
10/1/2014Nathaniel E DavidDirectorSell1,350$32.60$44,010.00View SEC Filing  
9/2/2014Nathaniel E DavidDirectorSell1,540$37.37$57,549.80View SEC Filing  
8/4/2014Keith R LeonardCEOSell1,828$35.10$64,162.80View SEC Filing  
8/4/2014Nathaniel E DavidDirectorSell1,505$33.08$49,785.40View SEC Filing  
8/1/2014Keith R LeonardCEOSell3,656$32.80$119,916.80View SEC Filing  
7/2/2014John W SmitherCFOSell2,250$40.00$90,000.00View SEC Filing  
7/2/2014Keith R LeonardCEOSell8,925$39.47$352,269.75View SEC Filing  
7/2/2014Nathaniel E DavidDirectorSell1,778$39.20$69,697.60View SEC Filing  
6/16/2014Keith R LeonardCEOSell1,743$36.58$63,758.94View SEC Filing  
6/2/2014Keith R LeonardCEOSell3,486$32.54$113,434.44View SEC Filing  
6/2/2014Nathaniel E DavidDirectorSell1,230$32.56$40,048.80View SEC Filing  
5/1/2014Keith LeonardCEOSell3,400$32.56$110,704.00View SEC Filing  
5/1/2014Nathaniel DavidDirectorSell1,200$32.60$39,120.00View SEC Filing  
4/1/2014Jeffrey WebsterVPSell4,000$39.36$157,440.00View SEC Filing  
4/1/2014Keith LeonardCEOSell13,260$39.08$518,200.80View SEC Filing  
3/20/2014John SmitherCFOSell1,125$43.78$49,252.50View SEC Filing  
3/3/2014Jeffrey WebsterVPSell4,000$49.55$198,200.00View SEC Filing  
3/3/2014Nathaniel DavidDirectorSell5,099$49.18$250,768.82View SEC Filing  
2/20/2014John SmitherCFOSell2,250$49.75$111,937.50View SEC Filing  
2/14/2014John SmitherCFOSell1,125$50.00$56,250.00View SEC Filing  
2/3/2014Jeffrey WebsterVPSell4,000$45.40$181,600.00View SEC Filing  
2/3/2014Keith LeonardCEOSell12,740$45.35$577,759.00View SEC Filing  
2/3/2014Nathaniel DavidDirectorSell5,000$45.31$226,550.00View SEC Filing  
1/21/2014John SmitherCFOSell1,125$42.54$47,857.50View SEC Filing  
1/2/2014Jeffrey WebsterVPSell4,000$37.38$149,520.00View SEC Filing  
1/2/2014Keith LeonardCEOSell12,480$37.38$466,502.40View SEC Filing  
12/2/2013Jeffrey WebsterVPSell4,000$38.69$154,760.00View SEC Filing  
12/2/2013Keith LeonardCEOSell12,220$38.95$475,969.00View SEC Filing  
12/2/2013Nathaniel DavidDirectorSell4,800$38.72$185,856.00View SEC Filing  
11/1/2013Jeffrey D WebsterVPSell4,000$44.90$179,600.00View SEC Filing  
11/1/2013Keith R LeonardCEOSell11,960$44.22$528,871.20View SEC Filing  
11/1/2013Nathaniel E DavidDirectorSell4,698$43.93$206,383.14View SEC Filing  
9/16/2013Keith LeonardCEOSell2,860$33.62$96,153.20View SEC Filing  
9/10/2013John W SmitherCFOSell40,000$30.02$1,200,800.00View SEC Filing  
9/10/2013Keith KleinGeneral CounselSell4,500$32.00$144,000.00View SEC Filing  
9/10/2013Nathaniel E DavidDirectorSell6,376$31.00$197,656.00View SEC Filing  
9/3/2013Jeffrey WebsterVPSell4,000$26.11$104,440.00View SEC Filing  
9/3/2013Keith LeonardCEOSell8,580$26.12$224,109.60View SEC Filing  
9/3/2013Nathaniel DavidDirectorSell3,375$26.12$88,155.00View SEC Filing  
8/1/2013Jeffrey D WebsterVPSell4,000$26.76$107,040.00View SEC Filing  
8/1/2013John W SmitherCFOSell10,000$26.80$268,000.00View SEC Filing  
8/1/2013Keith R LeonardCEOSell8,385$26.73$224,131.05View SEC Filing  
8/1/2013Nathaniel E DavidDirectorSell3,301$26.76$88,334.76View SEC Filing  
7/15/2013Keith R LeonardCEOSell1,365$28.90$39,448.50View SEC Filing  
7/1/2013Jeffrey D WebsterVPSell4,000$27.06$108,240.00View SEC Filing  
7/1/2013Keith R LeonardCEOSell8,190$27.10$221,949.00View SEC Filing  
7/1/2013Nathaniel E DavidDirectorSell3,225$27.07$87,300.75View SEC Filing  
6/28/2013Keith KleinGeneral CounselSell4,500$27.00$121,500.00View SEC Filing  
6/17/2013John W SmitherCFOSell6,000$26.00$156,000.00View SEC Filing  
6/17/2013Keith R LeonardCEOSell1,332$25.69$34,219.08View SEC Filing  
6/17/2013Nathaniel E DavidDirectorSell1,538$26.00$39,988.00View SEC Filing  
6/7/2013Jeffrey D WebsterVPSell4,000$25.00$100,000.00View SEC Filing  
6/3/2013Keith R LeonardCEOSell6,663$21.25$141,588.75View SEC Filing  
5/31/2013Jeffrey D WebsterVPSell4,000$22.26$89,040.00View SEC Filing  
5/1/2013Nathaniel E DavidDirectorSell2,625$21.42$56,227.50View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Kythera Biopharmaceuticals (NASDAQ:KYTH)
News IconSodium Deoxycholate for Submental Contouring (NASDAQ:KYTH) - October 22 at 5:33 PM
News IconBlackThorn Therapeutics Launches to Develop Novel, Targeted Treatments for Neurobehavioral Disorders (NASDAQ:KYTH) - October 20 at 6:11 PM logoBlackThorn Therapeutics Launches to Develop Novel, Targeted Treatments for Neurobehavioral Disorders - Business Wire (press release) (NASDAQ:KYTH) - October 20 at 11:34 AM logoPfenex Inc. Announces Formation of Scientific Advisory Board - PR Newswire (press release) (NASDAQ:KYTH) - October 20 at 11:34 AM logoPfenex Inc. Announces Formation of Scientific Advisory Board (NASDAQ:KYTH) - October 19 at 6:13 PM
News Icon$67 Million Thousand Oaks Multifamily Sale Closed by Marcus & Millichap’s IPA Division (NASDAQ:KYTH) - October 5 at 11:08 AM
News IconKythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) Updated Broker Price Targets - The De Soto Edge (NASDAQ:KYTH) - October 4 at 5:43 PM
News IconKythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) Latest Broker Views - NewsDen (NASDAQ:KYTH) - October 1 at 11:14 AM
News IconKythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) Latest Broker Coverage - NewsDen (NASDAQ:KYTH) - September 29 at 5:50 PM
News IconBroker Roundup For Kythera Biopharmaceuticals, Inc. (NASDAQ ... - The De Soto Edge (NASDAQ:KYTH) - September 29 at 5:50 PM
News IconIMT Westlake Village Apartment Complex in Los Angeles Sells for $88.2M - REBusinessOnline (NASDAQ:KYTH) - September 1 at 8:56 AM
News IconIMT Westlake Village Apartment Complex in Los Angeles Sells for $88.2M (NASDAQ:KYTH) - August 31 at 10:43 AM
News Icon$88.25 Million Ventura County Multifamily Sale Closed by Marcus & Millichaps IPA Division (NASDAQ:KYTH) - August 30 at 5:55 PM
News IconMedical Aesthetics Market Worth $69786 Million by 2021 - MENAFN.COM (NASDAQ:KYTH) - August 11 at 6:09 PM logoMedical Aesthetics Market Worth $69,786 Million by 2021 (NASDAQ:KYTH) - August 10 at 8:52 AM
News IconTeva/Actavis merger's FTC scrutiny creates another pharma winner - BioWorld Online (NASDAQ:KYTH) - August 4 at 6:14 PM logoMannKind (MNKD) Assumes Responsibility for Distribution of Afrezza; Launches Patient Reimbursement Programs - (NASDAQ:KYTH) - August 1 at 5:45 PM logoMannkind Assumes Responsibility for Distribution of Afrezza® and Launches Patient Reimbursement and Adherence Support Programs (NASDAQ:KYTH) - August 1 at 10:38 AM logoSienna Biopharmaceuticals Announces Second Closing of Series A Financing - Business Wire (press release) (NASDAQ:KYTH) - July 13 at 6:17 PM logoSienna Biopharmaceuticals Announces Second Closing of Series A Financing (NASDAQ:KYTH) - July 13 at 8:52 AM logoSienna Biopharmaceuticals Announces Second Closing of Series A Financing - Yahoo Finance (NASDAQ:KYTH) - July 12 at 6:09 PM logoRecently Issued Stock Ratings For Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) - Fiscal Standard (NASDAQ:KYTH) - July 3 at 5:27 PM logoSanifit Appoints Preston S. Klassen MD, MHS as Chief Medical Officer and Announces new US Subsidiary - PR Newswire (press release) (NASDAQ:KYTH) - June 7 at 8:29 AM
News IconLatest Analyst Ratings For Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) - Share Trading News (NASDAQ:KYTH) - May 20 at 8:00 PM logoArena Q1: A Beat And A New CEO - Seeking Alpha (NASDAQ:KYTH) - May 10 at 8:36 PM logoSanifit Expands Board With Senior Hire - PR Newswire (press release) (NASDAQ:KYTH) - May 10 at 8:36 PM logoArena Pharmaceuticals Announces Appointment of Amit D. Munshi as President and Chief Executive Officer - SYS-CON Media (press release) (NASDAQ:KYTH) - May 10 at 1:22 AM logoArena Pharma (ARNA) Taps Epirus Biopharma's Munshi as CEO - (NASDAQ:KYTH) - May 10 at 1:22 AM logo6 Reasons to Watch Kythera Biopharm Inc. (AGN, PFE) (NASDAQ:KYTH) - May 1 at 10:39 AM
News IconARCH leads $34 mln Series A financing in Sienna Biopharmaceuticals - Thomson Reuters' peHUB (press release) (NASDAQ:KYTH) - April 29 at 8:59 PM logoSienna Biopharmaceuticals Announces $34 Million Series A Financing - Business Wire (press release) (NASDAQ:KYTH) - April 28 at 9:55 PM
News IconKythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) Broker Price Targets For The Coming Week - Share Trading News (NASDAQ:KYTH) - April 24 at 10:58 PM logoIs Ellie Mae Inc (ELLI) A Good Stock To Buy? (NASDAQ:KYTH) - December 1 at 4:38 PM logoShould You Buy Kennametal Inc. (KMT)? (NASDAQ:KYTH) - November 27 at 3:46 PM logoAllergan Successfully Completes Kythera Acquisition; Adds Game-Changing KYBELLA Treatment for Double-Chin (NASDAQ:KYTH) - October 8 at 9:54 AM logoKYTHERA® Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss (NASDAQ:KYTH) - October 8 at 9:54 AM logoALLERGAN PLC. Financials (NASDAQ:KYTH) - October 6 at 1:04 PM logoXBI’s Top Ten Small-Cap Stocks Perform on Par with Large-Caps (NASDAQ:KYTH) - October 2 at 4:07 PM logoKYTHERA Biopharmaceuticals, Inc. Earnings Q2, 2015 (NASDAQ:KYTH) - October 2 at 10:55 AM logoKYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acqu (NASDAQ:KYTH) - October 1 at 4:24 PM logoKYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:KYTH) - September 28 at 4:07 PM logoKYTHERA Files IND Application for Male Hair Loss Treatment (NASDAQ:KYTH) - September 23 at 5:05 PM logoKYTHERA(R) Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss (NASDAQ:KYTH) - September 22 at 9:25 AM logoKYTHERA Files Regulatory Application for Kybella in EU (NASDAQ:KYTH) - August 19 at 4:30 PM logoKYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:KYTH) - August 18 at 4:33 PM logoKYTHERA(R) Biopharmaceuticals Submits Marketing Authorization Application in the European Union for ATX-101 as First-in-Class Treatment for the Reduction of Submental Fat (NASDAQ:KYTH) - August 18 at 9:22 AM logoKYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement (NASDAQ:KYTH) - August 6 at 4:07 PM logoAllergan reports better-than-expected revenue (NASDAQ:KYTH) - August 6 at 9:33 AM logoWhat to Expect From Allergan Earnings (NASDAQ:KYTH) - August 5 at 2:05 PM logoKYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financia (NASDAQ:KYTH) - August 5 at 8:18 AM


Kythera Biopharmaceuticals (NASDAQ:KYTH) Chart for Tuesday, October, 25, 2016

Last Updated on 10/25/2016 by Staff